Boston Scientific Announces
'TAXUS® Stent Assurance Program'
Company to offer stent at no charge if re-intervention required
NATICK, Mass., Oct. 13 -- Boston Scientific Corporation (NYSE: BSX - News)
today introduced a new program that will offer participating medical centers
in the United States a TAXUS® Express2™ stent system at no additional
charge if a patient requires a re-intervention due to in-stent restenosis of
a previously implanted TAXUS Express2 stent system. The program will run from
January 1, 2006 to December 31, 2006.
"As the worldwide drug-eluting stent market leader, the TAXUS stent system continues to be the drug-eluting stent-of-choice for physicians and their patients," said Paul LaViolette, Boston Scientific's Chief Operating Officer. "We believe the TAXUS stent system is the best in its class, with its remarkable efficacy and safety record and excellent deliverability. This confidence has led us to take the unprecedented step of introducing a new program called the TAXUS Stent Assurance Program. The program will provide participating medical centers -- at no additional charge -- a TAXUS stent if any of their patients return requiring a re-intervention due to in-stent restenosis."
"Boston Scientific's TAXUS stent system has demonstrated excellent safety and efficacy results during its rigorous series of clinical trials and registries," said Donald Baim, M.D., Director, Center of Integration of Medicine and Innovative Technology at Brigham and Women's Hospital. "I believe that the introduction of the TAXUS Stent Assurance Program demonstrates the Company's commitment to standing behind this innovative technology, which continues to change the way physicians treat coronary artery disease."
"The TAXUS Stent Assurance Program is our way of saying that we stand squarely and confidently behind our product," said Hank Kucheman, President of Boston Scientific's Interventional Cardiology business. "The revolutionary TAXUS stent system remains the global market-leading drug-eluting stent system and has now benefited more than 1.8 million patients worldwide."
To be eligible for participation in the TAXUS Stent Assurance Program, a medical center must enroll in advance through their Boston Scientific sales representative. Subject to the terms of the program, if a participating medical center implants a TAXUS Express2 stent and the patient returns to the medical center with a stent that restenoses within 12 months of implantation, Boston Scientific will provide the medical center with a TAXUS Express2 stent system at no additional charge.
For more information on the terms of the TAXUS Stent Assurance Program, contact your Boston Scientific sales representative or visit http://www.taxus-stent.com.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information on the Company, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies, intellectual property, and other factors described in the Company's filings with the Securities and Exchange Commission.
CONTACT:
Milan Kofol
508-650-8569 (Office)
Investor Relations
Boston Scientific Corporation
Paul Donovan
508-650-8541 (Office)
508-667-5165 (Mobile)
Media Relations
Boston Scientific Corporation
Source: Boston Scientific Corporation
|
